AOD-9604 before and after claims: what the actual trials showed

Last updated 2026-07-25

What is AOD-9604 supposed to do, according to the people who developed it?

AOD-9604 is a fragment of human growth hormone, specifically the region of the hGH molecule (amino acids 176-191) that researchers linked to fat metabolism without the growth-promoting effects of full-length hGH. The idea was to isolate the piece of the hormone that triggers lipolysis (fat breakdown) and blocks lipogenesis (fat storage), while dropping the piece that drives tissue growth and the side effects that come with it, like joint swelling and insulin resistance. That's a real, reasonably elegant idea, and it is why AOD-9604 got attention in the 2000s as an obesity drug candidate. A 2004 paper in Current Opinion in Investigational Drugs summarized the metabolic rationale and early findings for the compound, describing its proposed fat-metabolizing action as the basis for its development as an anti-obesity agent ^[1]. A separate 2006 review of the obesity drug pipeline placed AOD-9604 among a field of candidates being tested at the time for weight loss, alongside other mechanisms in development ^[2]. So the fragment logic isn't invented marketing. It came out of legitimate endocrinology research. The problem is what happened when that logic got tested in actual humans over weeks and months, not in a single blood draw. Before you look at any transformation photo tied to this peptide, it helps to understand that the entire commercial case rests on this fragment hypothesis working out in clinical trials. It didn't hold up the way the early rationale suggested it might. For a side-by-side look at how that plays out against a peptide with an actual approved indication, see the comparison of AOD-9604 vs tesamorelin.

Did AOD-9604 actually beat placebo in human obesity trials?

This is the question that matters most, and the honest answer is no, not convincingly. AOD-9604 went through human trials for obesity, including work sponsored by the Australian company that originally developed it (Metabolic Pharmaceuticals). Public trial registries and pipeline reviews from the mid-2000s tracked the compound through Phase II and toward Phase III testing for weight loss ^[2]. The compound generated real interest because early-phase signals looked promising enough to justify larger trials. But the pattern that shows up again and again in peptide and obesity drug development, AOD-9604 included, is that small early trials can look encouraging and larger, better-controlled trials often show the effect shrinking or disappearing. The 2004 Current Opinion in Investigational Drugs summary describes the metabolic and fat-reduction findings reported for AOD-9604 up to that point, and it's worth being precise about what a summary paper like this can and cannot tell you: it reports what was found in the studies available at the time, not an independent confirmation that the drug produces meaningful, durable fat loss in a large general population ^[1]. The practical, blunt version readers want: no peer-reviewed, adequately powered Phase III trial has been published showing that AOD-9604 produces weight loss that clearly separates from placebo in humans. That absence is the central fact of this entire topic. If a decisive trial existed showing real separation, the compound would look completely different in the regulatory landscape today, and it doesn't. AOD-9604 has no FDA approval for any indication, and it does not appear in the FDA's Drugs@FDA database of approved drug products [drugsfda]. If you want the mechanism-versus-outcome gap laid out plainly, that's exactly what AOD-9604 vs tesamorelin walks through.

So what do the 'before and after' photos people share actually represent?

Almost none of them come from controlled trials. Overwhelmingly, before-and-after photos circulating for AOD-9604 come from individual users running the peptide alongside a calorie deficit, exercise, and often other compounds, then attributing the visible change to the peptide alone. That's not a personal accusation against any single person posting a photo. It is just how attribution works when there's no control group. If someone cuts calories, adds cardio, and injects a peptide for eight weeks, and they lose fat, the honest statement is 'I lost fat while doing several things at once,' not 'this peptide caused my fat loss.' A photo cannot separate those variables. A randomized, placebo-controlled trial can, and that is exactly the kind of trial that has not been published showing AOD-9604 wins decisively. There's also a selection bias problem built into social proof. People who don't see results from a product rarely post about it. The photos you see online are a filtered sample of outcomes, not a representative one, and filtered samples are close to useless for judging whether a compound works. If someone in those photos is also running a stimulant-based fat-loss approach at the same time, the attribution problem gets worse, not better; see AOD-9604 vs clenbuterol for how that comparison plays out.

Does AOD-9604 show up on doping tests or bloodwork differently than real HGH?

Yes, and this is one of the more well-studied angles on this peptide, separate from the weight-loss question. A 2013 paper in Drug Testing and Analysis specifically examined whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping, and found that AOD-9604 does not influence that assay ^[3]. That matters for athletes and for anyone assuming this fragment would show up on a standard hGH panel the same way full hGH would. It doesn't, according to that assay-specific finding. Separately, the broader anti-doping analytical chemistry field has developed methods aimed at detecting peptide drugs and their analogs, including smaller fragments like AOD-9604, in urine and blood. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covered analytical approaches for detecting emerging and non-approved therapeutics in doping controls ^[4], and a companion 2014 review in Expert Review of Proteomics covered the current status and direction of detecting peptidic drugs and drug candidates specifically ^[5]. A 2016 paper in the Journal of Separation Science described a method using direct urine injection, liquid chromatography, and ion mobility mass spectrometry to screen for peptides under 2 kDa, a size range that includes fragments like AOD-9604 ^[6]. The upshot: standard hGH isoform testing won't catch AOD-9604, but purpose-built peptide screening methods are actively being developed and used specifically because regulators know fragments like this one are being used outside of trials.

How does AOD-9604's evidence record compare to other fat-loss and body-composition peptides?

This is where it helps to see the trial landscape side by side rather than taking any one compound's marketing at face value.

If you're specifically weighing AOD-9604 against a GHRH analog with an actual approved indication, the comparison is worth reading in full at AOD-9604 vs tesamorelin. If you're weighing it against a stimulant-based approach instead, see AOD-9604 vs clenbuterol. Neither comparison changes the core fact here: AOD-9604 sits in the weakest evidence tier of that group for the specific claim of fat loss in humans.

Is there any legitimate research use for AOD-9604 outside of fat-loss marketing?

There's emerging interest in peptide therapies, including AOD-9604, in musculoskeletal and orthopaedic research contexts, separate from the obesity angle. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics broadly, discussing applications, challenges, and future directions across a class of compounds that includes fragments like this one ^[7]. A companion 2026 paper in Sports Medicine reviewed the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[8]. These are worth naming honestly: they represent an active research conversation about peptides in a different clinical context (joint and tissue repair, athletic recovery), not a validation of AOD-9604 for fat loss. It would be a mistake to point to orthopaedic peptide research as if it answers the weight-loss question. It doesn't. It just tells you the broader peptide research field is active and still working out where these molecules actually help and where they don't.

Is AOD-9604 legal to buy, and is it FDA-approved?

AOD-9604 has no FDA approval for any human indication. You can confirm this directly by checking the FDA's own Drugs@FDA database of approved drug products [drugsfda], which does not list it. The compounding angle is more nuanced and it's the one most people asking about sourcing actually care about. Under federal law, compounding pharmacies can prepare individualized prescriptions using bulk drug substances, but only certain substances are permitted for that purpose. The FDA maintains a Bulks List for substances usable under Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 CFR 216.23 ^[9], and a separate Bulks List for 503B outsourcing facilities at 21 CFR 216.24 ^[10]. The statutory basis for pharmacy compounding itself is 21 U.S.C. 353a ^[11]. The FDA also maintains a running list of bulk drug substances that have been nominated for compounding use and are under evaluation ^[12], and a general compounding substances page explaining how that evaluation process works ^[13]. Whether AOD-9604 specifically appears on an approved Bulks List, and under what conditions, is something that changes as FDA nomination decisions are updated, so check the current FDA list directly rather than relying on a seller's claim. Separately, under 21 CFR 201.128, a product's 'intended use' for regulatory purposes is defined by how it's labeled, advertised, and represented ^[14], which is exactly why legitimate providers are careful not to market a compounded peptide with disease-treatment or weight-loss cure language. That's not a technicality; it's the legal line that determines what can be said about a product at all.

If someone still wants to try it, what's the responsible way to do that?

If you've read the trial record above and still want to proceed, the responsible path is a provider-reviewed one, not a blind purchase from an unregulated online seller with no clinical oversight. That means working with a licensed prescriber who reviews your health history, explains that the weight-loss evidence for AOD-9604 is weak and unresolved, and sources the peptide through a pharmacy that compounds under the legal framework described above rather than an unregulated supplement channel. AOD-9604 Co's provider-reviewed route connects readers to that kind of oversight and to a fulfilling pharmacy partner, rather than to a straight-to-consumer supplement listing making unqualified fat-loss promises. Whatever route you take, don't skip the injection technique question. Poor technique with any subcutaneous peptide raises injection site risk unrelated to whether the compound itself works, and that's a separate, practical problem worth solving regardless of where you land on the efficacy question. See AOD-9604 how to inject for that piece specifically.

What should someone realistically expect if they try AOD-9604 for fat loss?

Realistically: don't expect the compound itself to be the reason you lose fat, because the trial data doesn't support that expectation. Expect, at best, an unproven adjunct to a calorie deficit and resistance training, the same two levers that drive almost all documented fat loss in humans regardless of what peptide or drug is layered on top. If you see meaningful fat loss while using AOD-9604, the honest interpretation, given the trial record, is that the deficit and the training did the work, not the peptide. That's not a cynical take. It's the plain reading of a trial history where the compound has not shown a clear separation from placebo in published human obesity research ^[1][2]. Compare that to tesamorelin, which has an actual FDA-approved indication for a specific, defined form of fat accumulation, and you can see the gap in evidence quality directly. That gap is the whole story here, and it's worth reading in full at AOD-9604 vs tesamorelin before you spend money either way.

Frequently asked questions

Do AOD-9604 before and after photos prove it works for fat loss?

No. Before-and-after photos almost never come from controlled trials, so they can't separate the peptide's effect from diet, exercise, or other compounds used at the same time. The actual human obesity trials for AOD-9604 did not show weight loss clearly beating placebo ^[1][2], which is why photo evidence should be treated as anecdote, not proof.

Has AOD-9604 passed Phase III trials for weight loss?

There is no published, peer-reviewed Phase III trial showing AOD-9604 produces weight loss that clearly separates from placebo. Mid-2000s pipeline reviews tracked it through earlier trial phases as an obesity candidate ^[2], but no decisive later-phase result has been published confirming the effect at scale.

Is AOD-9604 FDA-approved?

No. AOD-9604 does not appear in the FDA's Drugs@FDA database of approved drug products for any indication. It has never received FDA approval as a weight-loss drug or for any other use.

Will AOD-9604 show up on a growth hormone doping test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping ^[3]. However, newer peptide-specific screening methods, including mass spectrometry approaches for small peptides, have been developed separately to detect compounds like this one ^[6].

How is AOD-9604 different from full human growth hormone?

AOD-9604 is a fragment representing amino acids 176-191 of the hGH molecule, isolated because researchers believed that region drove fat metabolism without the growth-promoting effects of full hGH ^[1]. The rationale was to keep the fat-related action and drop the side effects tied to tissue growth, but that rationale hasn't translated into confirmed clinical weight-loss results.

Is AOD-9604 the same as tesamorelin?

No. Tesamorelin is a GHRH analog with FDA approval for reducing visceral fat in HIV-associated lipodystrophy, a specific approved indication. AOD-9604 is an hGH fragment with no FDA approval and no published Phase III weight-loss trial showing it beats placebo. See the full comparison at AOD-9604 vs tesamorelin.

Can a compounding pharmacy legally make AOD-9604?

Compounding pharmacies can only use bulk substances permitted under 21 U.S.C. 353a and listed or evaluated under the FDA's 503A and 503B Bulks List processes (21 CFR 216.23 and 216.24) ^[9][10]. Whether AOD-9604 currently qualifies depends on the FDA's current nominated substances list ^[12], which changes over time, so check it directly.

Why do some people still report fat loss on AOD-9604?

Most reported fat loss happens alongside a calorie deficit, added exercise, or other compounds, none of which a personal report can separate out. Without a placebo-controlled comparison, individual results can't tell you whether the peptide contributed anything beyond the diet and training changes made at the same time.

Is AOD-9604 safer than full hGH because it doesn't affect growth?

That was the original rationale, that removing the growth-promoting portion of the hGH molecule would avoid side effects like joint swelling and insulin resistance seen with full hGH ^[1]. That mechanistic reasoning is real, but a favorable side-effect theory is not the same as confirmed weight-loss efficacy, which the human trials have not established ^[1][2].

Does AOD-9604 have any confirmed use outside of fat loss?

Peptide research broadly, including compounds like AOD-9604, has drawn interest in orthopaedic and musculoskeletal contexts, as covered in a 2026 review in JAAOS Global Research & Reviews ^[7] and a 2026 Sports Medicine review of peptide therapies for injuries and athletic performance ^[8]. Neither paper validates AOD-9604 for fat loss; they describe a separate, ongoing research area.

What's the most honest summary of the AOD-9604 trial record?

AOD-9604 has a plausible fat-metabolism mechanism and went through real obesity trials, but no published trial has shown weight loss that clearly separates from placebo, and it has no FDA approval for any use ^[1][2][drugsfda]. Treat marketing claims and photos with that gap in mind.

Should I try AOD-9604 if I want to lose fat?

Given the weak trial record, it shouldn't be your primary fat-loss strategy; a calorie deficit and resistance training remain the two levers with actual evidence behind them. If you still want to try it, do so through a provider-reviewed route with a licensed prescriber and a pharmacy operating under the legal compounding framework, not an unregulated online seller.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's proposed fat-metabolizing mechanism (hGH fragment 176-191) and reported metabolic findings underlying its development as an obesity drug candidate.
2. PubMed, Current Opinion in Investigational Drugs (2006): Places AOD-9604 among obesity drug candidates in clinical development as of 2006, tracking its pipeline progress at the time.
3. PubMed, Drug Testing and Analysis (2013): Found that AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing.
4. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs, including peptides, in doping controls.
5. PubMed, Expert Review of Proteomics (2014): Reviews current status and future directions for detecting peptidic drugs and drug candidates in sports doping.
6. PubMed, Journal of Separation Science (2016): Describes a method using direct urine injection, liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa.
7. PubMed, JAAOS Global Research & Reviews (2026): Reviews therapeutic peptides in orthopaedics, covering applications, challenges and future directions for this compound class.
8. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
9. eCFR, 21 CFR 216.23: Establishes the 503A Bulks List governing which bulk drug substances compounding pharmacies may legally use.
10. eCFR, 21 CFR 216.24: Establishes the 503B Bulks List governing bulk drug substance use by outsourcing facilities.
11. Cornell LII, 21 U.S.C. 353a: Provides the statutory basis for pharmacy compounding of drug products in the United States.
12. FDA, Bulk drug substances nominated for use in compounding: Lists bulk drug substances currently nominated for compounding use and under FDA evaluation.
13. FDA, Bulk drug substances used in compounding under section 503A: Explains the FDA's process for evaluating and listing bulk substances usable in 503A compounding.
14. eCFR, 21 CFR 201.128: Defines how a drug product's intended use is determined by its labeling, advertising and representations.
15. FDA, Drugs@FDA database: Confirms AOD-9604 does not appear as an FDA-approved drug product for any indication.